Attisano, Liliana
University of Toronto
Modelling brain metastasis
|
2020/2021
:
$100,000
2021/2022
:
$100,000
|
Britton, Robert
Simon Fraser University
Small molecule inhibitors of O GlcNAc transferase: validation of a new anticancer target
|
2020/2021
:
$100,000
2021/2022
:
$100,000
|
Diallo, Jean Simon
Ottawa Hospital Research Institute
Enhancing oncolytic virus efficacy using effector peptides
|
2020/2021
:
$100,000
2021/2022
:
$100,000
|
Ferbeyre, Gerardo
Université de Montréal
Targeting a novel pyruvate metabolic cycle to restore the senescent tumour suppression mechanism in tumours
|
2020/2021
:
$100,000
2021/2022
:
$100,000
|
Ferguson, Sarah
Princess Margaret Cancer Centre UHN
Bariatric surgery for fertility sparing treatment of atypical hyperplasia and grade 1 cancer of the endometrium (B FiERCE): a feasibility study
|
2020/2021
:
$63,372
2021/2022
:
$63,372
2022/2023
:
$63,372
|
Goping, Ing Swie
University of Alberta
Sublethal apoptosis as a driver of breast cancer recurrence
|
2020/2021
:
$100,000
2021/2022
:
$100,000
|
Jaakkimainen, Liisa
Institute for Clinical Evaluative Sciences
Identifying pathways for cancer care from family physicians' electronic medical records
|
2020/2021
:
$99,746
2021/2022
:
$99,945
|
Kim, Dennis
Princess Margaret Cancer Centre UHN
Clonal stromapoiesis and BM microenvironment in leukemias and HCT
|
2020/2021
:
$100,000
2021/2022
:
$100,000
|
Koromilas, Antonis
Jewish General Hospital
2B or not 2B: that is the question about KRAS function.
|
2020/2021
:
$100,000
2021/2022
:
$100,000
|
Li, Shawn (Shun Cheng)
Western University
Mechanism of resistance to anti PD 1/L1 immunotherapy and strategies to overcome resistance
|
2020/2021
:
$100,000
2021/2022
:
$100,000
|
McCaffrey, Luke
McGill University
Characterizing DCIS heterogeneity and disease progression
|
2020/2021
:
$100,000
2021/2022
:
$100,000
|
Olson, Michael
Ryerson University
MRCK inhibitor optimization for glioblastoma therapy
|
2020/2021
:
$100,000
2021/2022
:
$100,000
|
Park, Morag
McGill University
Developing therapeutic approaches to treat poor outcome metaplastic breast carcinomas
|
2020/2021
:
$100,000
2021/2022
:
$100,000
|
Reilly, Raymond
University of Toronto
Radiation nanomedicine combined with checkpoint immunotherapy for treatment of glioblastoma multiiforme (GBM)
|
2020/2021
:
$100,000
2021/2022
:
$100,000
|
Saleeb, Rola
St. Michael's Hospital
Using nanopore technology to develop rapid, real time, clinical molecular oncology testing
|
2020/2021
:
$99,225
2021/2022
:
$99,025
|
Shuhendler, Adam
University of Ottawa
Aldehydes as an imaging biomarker for lung cancer detection and staging by PET
|
2020/2021
:
$90,500
2021/2022
:
$100,000
|
Siegel, Peter
McGill University
Characterizing molecular mediators of leptomeningeal metastasis
|
2020/2021
:
$63,500
2021/2022
:
$66,500
2022/2023
:
$70,000
|
Simunovic, Marko
McMaster University
Pilot study of the rectal cancer checklist and a reminder system to improve pre operative surgeon evaluation of surgical margins among patients with rectal cancer
|
2020/2021
:
$84,467
2021/2022
:
$85,918
|
Stein, Lincoln
Ontario Institute for Cancer Research
Oncolytic virus therapy for U1 mutant cancers
|
2020/2021
:
$99,979
2021/2022
:
$99,979
|
Watson, Ian
McGill University
Use of oncolytic viruses to overcome immune checkpoint inhibitor resistance in melanoma
|
2020/2021
:
$100,000
2021/2022
:
$100,000
|
Watts, Tania
University of Toronto
Investigating the role of signal 4 on inflammatory monocytes in tissue resident memory T cell formation and control of melanoma during STING agonist therapy
|
2020/2021
:
$100,000
2021/2022
:
$100,000
|
Wright, Frances
Ontario Health
An automated algorithm to identify and characterize skin cancers from population based pathology reports
*co-funded with CIHR-IMHA
|
2020/2021
:
$100,000
2021/2022
:
$95,200
2022/2023
:
$4,800
|
Yong, V. Wee
University of Calgary
Unexpected expression of PD1 on brain tumour initiating cells: a novel regulator of glioblastoma growth
|
2020/2021
:
$100,000
2021/2022
:
$100,000
|
Zadeh, Gelareh
The Toronto Hospital (Western Division) UHN
Proteogenomics of meningiomas to facilitate molecular classification and identify novel therapeutic options
|
2020/2021
:
$100,000
2021/2022
:
$99,570
|